ImQuest Microbiology ESKAPE Antibacterial MIC


Services for Antibiotic Discovery and Development

In a world of rapidly evolving microorganisms, it is critical to expeditiously identify and develop new and novel antibacterial compounds. As part of our CRO functions, ImQuest BioSciences offers MicroSENS: a full service antibiotic development program uniquely combining in vitro, ex vivo and in vivo animal model efficacy and toxicity evaluations focused on the development of novel antibiotics targeting resistant microorganisms and ESKAPE pathogens.

The foundation of the MicroSENS program consists of a select panel of clinically relevant wild-type and antibiotic resistant microorganisms to assess the efficacy, range and mechanism of antibacterial and antifungal activity, and mechanisms of resistance. We offer services for all of the ESKAPE pathogens, as well as a wide variety of gram positive, gram negative and anaerobic organisms. Additionally, we offer services to identify antibacterial agents that inhibit the growth of biofilms and accelerate the evaluation of anti-tuberculosis products.

The MicroSENS program facilitates the rapid evaluation of compounds in well established in vitro antibacterial and antifungal assays and extends the evaluation of active compounds in well-defined antimicrobial animal models including the sepsis and neutropenic thigh models, as well as other unique and disease-specific animal models. Request a quote for Microbiology Services.

In Vitro Antimicrobial Evaluation Services

  • CLSI broth-based microdilution for MIC and MBC determination
  • Kill-curve analysis
  • Analysis of bactericidal versus bacteriostatic activity
  • Serum bactericidal effects assay
  • Post-antibiotic effect
  • Anti-Persister Cell Assays
  • Inhibition of biofilm development
  • Minimum Biofilm Inhibitory Concentration (MBIC)
  • Combination antimicrobial evaluations and Fractional Inhibitory Concentration (FIC) determination
  • Resistance selection and characterization
  • Microbial quantification and identification
  • Mechanism of action studies:
    • Macromolecular Synthesis Assays: radiolabelled precursor incorporation analysis
    • In vitro generation and characterization of spontaneous resistance mutations
    • β-lactamase Assays
    • DNA Topoisomerase and DNA Gyrase Assays

In Vivo Evaluation of Antimicrobial Agents

Available bacterial and fungal pathogens panels

  • Indication-specific microorganisms
  • Clinically-relevant Gram negative and Gram positive organisms
  • ESKAPE Pathogens
  • Anaerobic organisms
  • Tuberculosis
  • Biofilm Related Pathogens
  • Sexually Transmitted Disease Pathogens (gonorrhea, chlamydia, trichomonas and viral models for HSV, HIV and HPV)
  • Phenotypic and genetically-defined drug resistant microbe panels
    • Carbapenam resistant
    • Extended spectrum beta-lactam resistant (ESBL)
    • Methicillin resistant
    • Penicillin resistant
    • Vancomycin resistant
    • Linezolid resistant
    • NDM-1 resistant
    • Multi-drug resistant
    • Custom Microbe Panels (upon request)

Additional supportive services as part of the ImQuest SUCCESS platform:

  • ToxiSENS-in vitro and ex vivo toxicology services
  • PharmaSENS-pharmaceutical product characterization and formulation services
  • PrevSENS-antimicrobial STD prevention product development services

Visit our Resource Library for additional publications, abstracts, and white papers. Contact Us to learn more.

ImQuest BioSciences is a preclinical contract research and development organization (CRO) that provides service to evaluate the potential efficacy of new and novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer and inflammatory disease, including in vitro toxicology and pharmaceutical product characterization services.